EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Neurological Adverse Events Related to Immune Checkpoint Inhibitors: A Practical Review

François Zammit, Emmanuel Seront

Pharmaceuticals · 14.04.2024 · 17 (4) · 501

DOI: 10.3390/ph17040501 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 14.04.2024. Verfasst von François Zammit und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institut Roi Albert II, Department of Medical Oncology, Cliniques Universitaires Saint Luc, Avenue Hippocrate 10, 1200 Brussels, Belgium. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The increasing use of immune checkpoint inhibitors (ICI) in cancer therapy has brought attention to their associated neurotoxicities, termed neurological immune-related adverse events (n-irAEs). Despite their relatively rare incidence, n-irAEs pose a significant risk, potentially leading to severe, long-lasting disabilities or even fatal outcomes. This narrative review aims to provide a comprehensive overview of n-irAEs, focusing on their recognition and management. The review addresses a spectrum of n-irAEs, encompassing myositis, myasthenia gravis, various neuropathies, and central nervous system complications, such as encephalitis, meningitis, and demyelinating diseases. The key features of n-irAEs are emphasized in this review, including their early onset after initiation of ICIs, potential association with non-neurological irAEs and/or concurrent oncological response, the significance of ruling out other etiologies, and the expected improvement upon discontinuation of ICIs and/or immunosuppression. Furthermore, this review delves into considerations for ICI re-challenge and the intricate nature of n-irAEs within the context of pre-existing autoimmune and paraneoplastic syndromes. It underscores the importance of a multidisciplinary approach to diagnosis and treatment, highlighting the pivotal role of severity grading in guiding treatment decisions.

Schlagwörter

Stichwörter der Autor:innen

encephalitisimmune checkpoint inhibitors (ICIs)immunotherapymyasthenia gravisneurological immune-related adverse events (n-irAEs)neurotoxicity

Autor:innen und Institutionen

  • Institut Roi Albert II, Department of Medical Oncology, Cliniques Universitaires Saint Luc, Avenue Hippocrate 10, 1200 Brussels, Belgium.

Zitieren

APA

Zammit, F., & Seront, E. (2024). Neurological Adverse Events Related to Immune Checkpoint Inhibitors: A Practical Review. Pharmaceuticals, 17(4), 501. https://doi.org/10.3390/ph17040501

Vancouver

Zammit F, Seront E. Neurological Adverse Events Related to Immune Checkpoint Inhibitors: A Practical Review. Pharmaceuticals. 2024;17(4):501. doi:10.3390/ph17040501

BibTeX
@article{Zammit2024,
  author = {Zammit, François and Seront, Emmanuel},
  title = {Neurological Adverse Events Related to Immune Checkpoint Inhibitors: A Practical Review},
  journal = {Pharmaceuticals},
  year = {2024},
  volume = {17},
  number = {4},
  pages = {501},
  doi = {10.3390/ph17040501}
}
Kostenlos starten →